The Biosecure Act was left out of a key US defence bill that passed in the House last week, in a major win for Chinese CDMOs. Shares in WuXi AppTec (Shanghai, China) opened 10.5% higher on December 9 ...

Earlier this week, efforts to reduce U.S. reliance on biotechnology companies in China stalled when the BIOSECURE Act (“BIOSECURE” or the “Act”) was left out of this week’s continuing resolution (CR).

The BIOSECURE Act does not propose a blanket prohibition on biotech and pharmaceutical companies from partnering or transacting with the entities covered by the law. Likewise, the current draft of the ...

Legislation in the US that could have a dramatic impact on the businesses of five biotechs with links to China has been left out of a key bill, introducing a delay that will likely extend into the ...

Since the introduction of the BIOSECURE Act in January, named companies and U.S.-based biopharmas alike have speculated on what the legislation could mean for the life sciences industry. In this ...

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. With the Trump administration preparing to take office, the ...

As a scientist, I’ve devoted my career to advancing genomic sequencing to help us better understand diseases that impact us all. Genomic sequencing is a major driver of prevention, diagnosis, ...

After running up against a roadblock earlier this summer, the controversial BIOSECURE Act could gain new momentum next week. The U.S. House of Representatives is slated to consider the legislation ...

The US House of Representatives comprehensively voted in favour of the BIOSECURE Act, which will prohibit businesses in the US from contracting with various Chinese firms on national security grounds.

John Wilkerson is a Washington correspondent for STAT who writes about the politics of health care. He is also the author of the twice-weekly D.C. Diagnosis newsletter. You’re reading the web edition ...